Table 1.
Characteristics of Study Participants
| Variable | Total IBD N = 247 | CD N = 153 | UC N = 94 |
|---|---|---|---|
| Age (yrs), mean (SD) | 47.4 (14.8) | 48.2 (14.5) | 46.2 (15.3) |
| Women, n (%) | 156 (63.2) | 102 (66.7) | 54 (57.5) |
| White, n (%) | 210 (85.0) | 132 (86.8) | 78 (83.0) |
| >High school education, n (%) | 171 (69.2) | 109 (71.2) | 62 (66.0) |
| Annual Income, n (%) | |||
| <$50,000 | 58 (23.5) | 44 (28.8) | 14 (14.9) |
| ≥$50,000 | 171 (69.2) | 101 (66.0) | 70 (74.5) |
| Declined | 18 (7.3) | 8 (5.2) | 10 (10.6) |
| Immune therapy, n (%) | |||
| Any | 185 (74.9) | 116 (75.8) | 69 (73.4) |
| Biologic | 80 (32.4) | 70 (45.8) | 10 (10.6) |
| Oral corticosteroid | 9 (3.6) | 5 (3.3) | 4 (4.3) |
| Disease duration (yrs), mean (SD) | 20.8 (12.4) | 22.5 (12.1) | 18.2 (12.4) |
| Age of IBD onset (yrs), n (%) | |||
| ≤17 | 32 (13.0) | 20 (13.1) | 12(12.8) |
| 17–40 | 164 (66.4) | 103 (67.3) | 61 (64.9) |
| ≥40 | 51 (20.6) | 30 (19.6) | 21 (22.3) |
| Montreal Classification UC, n (%) | |||
| E1 | 14 (15.1) | ||
| E2 | 38 (40.9) | ||
| E3 | 41 (44.1) | ||
| Montreal Classification CD, n (%) | |||
| Localization | |||
| L1 | 66 (43.1) | ||
| L2 | 22 (13.7) | ||
| L3 | 67 (43.1) | ||
| L4 | 0 (0) | ||
| Behaviour | |||
| B1 | 65 (42.8) | ||
| B2 | 53 (34.9) | ||
| B3 | 34 (22.4) | ||
| Active diseasea, n (%) | 101 (41.7) | 75 (50.3) | 26 (28.0) |
| IBS, n (%) | 62 (25.1) | 44 (28.8) | 18 (19.2) |
| HADS-D ≥ 11 | 15 (6.1) | 11 (7.2) | 5 (5.32) |
| HADS-Ab ≥11 | 41 (16.6) | 27 (17.8) | 14 (14.9) |
| HADS-D, mean (SD) | 4.0 (3.7) | 4.3 (3.8) | 3.4 (3.5) |
| HADS-Ab, mean (SD) | 6.3 (4.1) | 6.6 (4.1) | 6.0 (4.2) |
| Current smoker, n (%) | 42 (16.6) | 29 (18.9) | 13 (13.8) |
| Physical comorbidity, n (%) | |||
| 0 | 81 (32.8) | 43 (28.1) | 38 (40.4) |
| 1 | 58 (23.5) | 36 (23.5) | 22 (23.4) |
| ≥2 | 108 (43.7) | 74 (48.4) | 34 (36.2) |
a5 missing; b1 missing